Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's DiseasePRNewsWire • 03/08/23
Eli Lilly Is Slashing Insulin Prices by 70%. Here's Why Investors Shouldn't Worry.The Motley Fool • 03/08/23
US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetesPRNewsWire • 03/08/23
Eli Lilly and Company (LLY) Presents at Cowen's 43rd Annual Health Care Conference (Transcript)Seeking Alpha • 03/06/23
Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world studyPRNewsWire • 03/06/23
AI Stock Headlines 5 Leaders Flashing Buy Signals As Market Rally Gains SteamInvestors Business Daily • 03/04/23
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast CancerPRNewsWire • 03/03/23
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554Business Wire • 03/02/23
Eli Lilly CEO says $35 for monthly insulin ‘should be the new standard in America'Market Watch • 03/01/23
DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual MeetingGlobeNewsWire • 03/01/23
Diabetes Giant Eli Lilly Slashes Insulin Prices 70% In A Move Its CEO Calls 'Aggressive'Investors Business Daily • 03/01/23